An Emerging Paradigm in Atherosclerosis: Focus on Subclinical Disease

References

• . Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005;46(8):1425–1433
   PubMed Web of Science ®Google Scholar
• . Libby P. Changing concepts of atherogenesis. J Intern Med. 2000; 247(3): 349–358
   PubMed Web of Science ®Google Scholar
• . Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking: a preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990;264(23):3018–3024
   PubMedGoogle Scholar
• . Newman WP, Freedman DS, Voors AW,. Relationship of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study. N Engl J Med. 1986;314(9):138–144
   PubMedGoogle Scholar
• . Berenson GS. Childhood risk factors predict adult risk associated with subclinical cardiovascular disease: the Bogalusa Heart Study. Am J Cardiol. 2002;90(10C):3L–7L
   PubMedGoogle Scholar
• . Tuzcu EM, Kapadia SR, Tutar E,. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001;103(22):2705–2710
   PubMed Web of Science ®Google Scholar
• . Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet. 1999;354(9186):1234–1241
   PubMed Web of Science ®Google Scholar
• . Ringqvist I, Fisher LD, Mock M,. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest. 1983;71(6):1854–1866
   PubMed Web of Science ®Google Scholar
• . Emond M, Mock MB, Davis KB,. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1994;90(6):2645–2657
   PubMedGoogle Scholar
• . Storstein O, Enge I, Erikssen EJ, Thaulow E. Natural history of coronary artery disease studied by coronary arteriography: a seven-year study of 795 patients. Acta Med Scand. 1981;210(1–2):53–58
   PubMedGoogle Scholar
• . Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. AHA/ACC Scientific Statement: Assessment of cardiovascular risk by use of multiple-risk factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 1999;34(4):1348–1359
   PubMed Web of Science ®Google Scholar
• . Smith SC Jr, Greenland P, Grundy SM. AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation. 2000;101(1):111–116
   PubMedGoogle Scholar
• . Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115–126
   PubMed Web of Science ®Google Scholar
• . Fuster V. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90(4):2126–2146
   PubMedGoogle Scholar
• . Moldovan NI, Goldschmidt-Clermont PJ, Parker-Thornburg J,. Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ Res. 2000;87(5):378–384
   PubMedGoogle Scholar
• . Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316(22):1371–1375
   PubMed Web of Science ®Google Scholar
• . Grundy SM. Coronary plaque as a replacement for age as a risk factor in global risk assessment. Am J Cardiol. 2001;88(2A):8E–11E
   PubMed Web of Science ®Google Scholar
• . Zaman AG, Helft G, Worthley SG, Badimon JJ. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis. 2000;149(2):251–266
   PubMedGoogle Scholar
• . Burke AP, Kolodgie FD, Farb A,. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation. 2001;103(7):934–940
   PubMedGoogle Scholar
• . Rosamond W, Flegal K, Furie K,; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25–e146
   PubMed Web of Science ®Google Scholar
• . Taylor AJ, Feuerstein I, Wong H,. Do conventional risk factors predict subclinical coronary artery disease? Results from the Prospective Army Coronary Calcium Project. Am Heart J. 2001;141(3):463–468
   PubMedGoogle Scholar
• . Blankenhorn DH, Azen SP, Kramsch DM,; MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119(10):969–976
   PubMedGoogle Scholar
• . Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344(8923):633–638
   PubMedGoogle Scholar
• . Pitt B, Mancini GBJ, Ellis SG,; PLAC I Investigators. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol. 1995;26(5):1133–1139
   PubMed Web of Science ®Google Scholar
• . Waters D, Higginson L, Gladstone P,. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89(3):959–968
   PubMedGoogle Scholar
• . Herd JA, Ballantyne CM, Farmer JA,. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997;80(3):278–286
   PubMed Web of Science ®Google Scholar
• . Crouse JR III, Byington RP, Bond MG,. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC II). Am J Cardiol. 1995;75(7):455–459
   PubMedGoogle Scholar
• . Nissen SE, Tuzcu EM, Schoenhagen P,; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–1080
   PubMed Web of Science ®Google Scholar
• . MacMahon S, Sharpe N, Gamble G,. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. Lipid Trial Research Group. Circulation. 1998;97(18):1784–1790
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Nicholls SJ, Sipahi I,; ASTEROID Investigators. Effect of a very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556–1565
   PubMed Web of Science ®Google Scholar
• . Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106(16):2055–2060
   PubMed Web of Science ®Google Scholar
• . Underhill HR, Yuan C, Zhao XQ,. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J. 2008;155(3):584.e1–e8
   PubMed Web of Science ®Google Scholar
• . Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001; 357(9256): 577–581
   PubMed Web of Science ®Google Scholar
• . Kastelein JJ, Akdim F, Stroes ES,; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–1443
   PubMed Web of Science ®Google Scholar
• . Crouse JR III, Raichlen JS, Riley WA,. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA. 2007;297(12):1344–1353
   PubMed Web of Science ®Google Scholar
• . Raggi P, Davidson M, Callister TQ,. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Circulation. 2005;112(4):563–571
   PubMedGoogle Scholar
• . Nicholls SJ, Tuzcu EM, Sipahi I,. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297(5):499–508
   PubMed Web of Science ®Google Scholar
• . Ballantyne CM, Raichlen JS, Nicholls SJ,; ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117(19):2458–2466
   PubMed Web of Science ®Google Scholar
• . Lorenz MW, Markus HS, Bots ML,. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459–467
   PubMed Web of Science ®Google Scholar
• . Baldassarre D, Amato M, Pustina L,. Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events. Atherosclerosis. 2007;191(2):403–408
   PubMedGoogle Scholar
• . Espeland MA, O'Leary DH, Terry JG, Morgan T, Evans G, Mudra H. Carotid intimal-media thickness as a surrogate for cardiovascular events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med. 2005;6(1):3
   PubMedGoogle Scholar
• . Mercuri M, Bond MG, Sirtori CR,. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 1996;101(6):627–634
   PubMedGoogle Scholar
• . Lowenstein CJ. Nitric oxide regulation of protein trafficking in the cardiovascular system. Cardiovasc Res. 2007;75(2):240–246
   PubMedGoogle Scholar
• . Nissen SE, Tuzcu EM, Schoenhagen P,; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29–38
   PubMed Web of Science ®Google Scholar
• . Ridker PM, Cannon CP, Morrow D,; Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–28
   PubMed Web of Science ®Google Scholar
• . Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724–730
   PubMed Web of Science ®Google Scholar
• . Ridker PM, Danielson E, Fonseca FA,; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207
   PubMed Web of Science ®Google Scholar
• . Sever PS. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)? Am J Med. 2005;118( suppl 12A):3–9
   PubMedGoogle Scholar
• . Pearson TA, Mensah GA, Alexander RW,; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511
   PubMed Web of Science ®Google Scholar
• . Redberg RF, Vogel RA, Criqui MH, Herrington DM, Lima JA, Roman MJ. 34th Bethesda Conference: Task force #3–What is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis? J Am Coll Cardiol. 2003;41(11):1886–1898
   PubMedGoogle Scholar
• . Greenland P, Bonow RO, Brundage BH,; American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography); Society of Atherosclerosis Imaging and Prevention; Society of Cardiovascular Computed Tomography. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation. 2007;115(3):402–426
   PubMed Web of Science ®Google Scholar
• . Redberg RF, Walsh J. Pay now, benefits may follow—the case of cardiac computed tomographic angiography. N Engl J Med. 2008;359(22):2309–2311
   PubMed Web of Science ®Google Scholar
• . Grundy SM. Age as a risk factor: you are as old as your arteries. Am J Cardiol. 1999;83(10):1455–1457, A7
   PubMedGoogle Scholar
• . Grundy SM, Cleeman JI, Merz CN,; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239
   PubMed Web of Science ®Google Scholar
• . National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3420
   PubMed Web of Science ®Google Scholar
• . Schartl M, Bocksch W, Koschyk DH,. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001;104(4):387–392
   PubMed Web of Science ®Google Scholar
• . Cannon CP, Giugliano RP, Blazing MA,; IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156(5):826–832
   PubMed Web of Science ®Google Scholar